Compass Pathways: Trade Idea Amid Regulatory Tailwinds and Binary Clinical Outcomes
Compass Pathways (CMPS) is a high-volatility biotech with positive Phase 3 data and favorable regulatory momentum in 2026. The stock trades near $14.86 with a market cap around $2.0B. This trade idea outlines a mid-term swing long (45 trading days) with an entry at $14.86, stop at $11.50, and a target of $20.00 while mapping the clinical, regulator…